CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06900595
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:55.513690+00:00
- Published At
- 2026-04-14T00:00:00+00:00
- Record Updated At
- 2026-04-14
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Locally Advanced Adrenal Cortical Carcinoma", "Metastatic Adrenal Cortical Carcinoma", "Recurrent Adrenal Cortical Carcinoma", "Stage III Adrenal Cortical Carcinoma AJCC v8", "Stage IV Adrenal Cortical Carcinoma AJCC v8", "Unresectable Adrenal Cortical Carcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-14"- protocolSection.identificationModule.nctId
"NCT06900595"- protocolSection.identificationModule.officialTitle
"A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.